Janney Montgomery Scott
CADL icon

Janney Montgomery Scott’s Candel Therapeutics CADL Stock Holding History

Janney Montgomery Scott’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$338K Buy
32,372
+900
+3% +$10K ﹤0.01% 2660
2026
Q2 		$324K Buy
31,472
+1,000
+3% +$7.55K ﹤0.01% 2685
2026
Q1 		$149K Buy
30,472
+3,400
+13% +$18.5K ﹤0.01% 2670
2025
Q4 		$153K Sell
27,072
-3,314
-11% -$17.8K ﹤0.01% 2837
2025
Q3 		$155K Buy
30,386
+3,096
+11% +$17.9K ﹤0.01% 2771
2025
Q2 		$138K Buy
27,290
+6,200
+29% +$31.9K ﹤0.01% 2615
2025
Q1 		$119K Buy
21,090
+10,765
+104% +$88K ﹤0.01% 2597
2024
Q4 		$90K Sell
10,325
-1,340
-11% -$7.92K ﹤0.01% 2637
2024
Q3 		$81K Buy
11,665
+50
+0.4% +$311 ﹤0.01% 2593
2024
Q2 		$72K Buy
+11,615
New +$87.2K ﹤0.01% 2548

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return

Janney Montgomery Scott's CADL Position: Q3 2026 in Review

Janney Montgomery Scott increased its Candel Therapeutics (CADL) stake by 2.9% in Q3 2026, buying an estimated $10K and bringing the position to 32,372 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #2660.

Janney Montgomery Scott first reported a position in CADL in Q2 2024 and has held it in 10 quarters since. 106 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Janney Montgomery Scott held 32,372 shares of Candel Therapeutics worth $338K as of Q3 2026.
  • Janney Montgomery Scott bought 900 Candel Therapeutics shares in Q3 2026, an estimated $10K.
  • Candel Therapeutics made up ﹤0.01% of Janney Montgomery Scott's portfolio in Q3 2026, its #2660 holding.
  • Janney Montgomery Scott first reported a position in Candel Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 106 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Janney Montgomery Scott's 13F filing for Q3 2026, filed 12 Nov 2026.